

Author Index Volume 20 (2008)

The issue number is given in front of the page numbers.

- Abematsu, Y., see Haga, Y. (4) 241–247
- Agbabiaka, T.B., J. Savović, R. Harris and E. Ernst, The development of a tool to assess the quality of case reports of adverse events (3) 123–133
- Appiah-Danquah, A., see Ofori-Adjei, D. (3) 113–122
- Austin, D., An epidemiological analysis of the ‘autism as mercury poisoning’ hypothesis (3) 135–142
- Bhansali, A., see Singh, N. (1,2) 45– 50
- Bo-Yang, Y., see Yue, W. (1,2) 51– 56
- Braslow, D., see Marks, D.H. (4) 231–240
- Breggin, P.R., see Marks, D.H. (4) 231–240
- Burashnikova, I.S., A.U. Ziganshin and L.E. Ziganshina, Attitudes to pharmaceutical promotion techniques among healthcare professionals in the Republic of Tatarstan, Russia (1,2) 57– 71
- Buttigieg, G.G., C. Savona-Ventura, K. Vella and O. Cassar, Cervical carcinoma in the Maltese population (4) 223–230
- Buttigieg, G.G., see Savona-Ventura, C. (3) 155–160
- Cassar, O., see Buttigieg, G.G. (4) 223–230
- Chen, Y., Z.A. Wu, C. Zhang and Z. Wu, Overview of safety monitoring of biologicals in China (4) 207–212
- Collier, J., see Fuentes, H. (1,2) 83– 89
- Couper, M., see Ofori-Adjei, D. (3) 113–122
- Crum, R.M., see Morrato, E.H. (3) 143–154
- Curbow, B., see Morrato, E.H. (3) 143–154
- Dhanaraj, E., see Singh, N. (1,2) 45– 50
- Dodoo, A.N.O., see Ofori-Adjei, D. (3) 113–122
- Eckermann, E.J., see Whitstock, M.T. (3) 161–167
- Ernst, E., see Agbabiaka, T.B. (3) 123–133
- Fan-Dian, Z., see Yue, W. (1,2) 51– 56
- Feinleib, M., see Morrato, E.H. (3) 143–154
- Fuentes, H., J. Collier, M. Sinnott and M. Whitby, “Scalpel safety”: Modeling the effectiveness of different safety devices’ ability to reduce scalpel blade injuries (1,2) 83– 89
- Fukano, K., see Haga, Y. (4) 241–247
- Grima, S., see Savona-Ventura, C. (3) 155–160
- Haga, Y., T. Yamanouchi, S. Matsukura, Y. Nagamatsu, K. Yoshidomi, K. Fukano, M. Kawano, Y. Abematsu, K. Matoba, T. Koga and T. Tonai, Advice for prevention of inadvertent respiratory placement of nasogastric feeding tube (4) 241–247

- Hama, R., Fatal neuropsychiatric adverse reactions to oseltamivir: Case series and overview of causal relationships (1,2) 5– 36
- Harris, R., see Agbabiaka, T.B. (3) 123–133
- Hou-Ming, X., see Yue, W. (1,2) 51– 56
- Huang, Q., Clinical risk management, medical negligence prevention and the law: A review (4) 185–197
- Huang, Q., Clinical risk analysis under the law of negligence: A new approach to medical negligence prevention (4) 199–205
- Jimmy, B., see Jose, J. (3) 169–180
- Jose, J., P.G.M. Rao and B. Jimmy, Adverse drug reactions to fluoroquinolone antibiotics – Analysis of reports received in a tertiary care hospital (3) 169–180
- Jureidini, J.N., L.B. McHenry and P.R. Mansfield, Clinical trials and drug promotion: Selective reporting of study 329 (1,2) 73– 81
- Kapp, M.B., Legal issues in dementia (1,2) 91–103
- Kawano, M., see Haga, Y. (4) 241–247
- Koga, T., see Haga, Y. (4) 241–247
- Kruszewski, S.P. and R.P. Paczynski, Atypical antipsychotic agents for the schizophrenia prodrome: Not a clear first choice (1,2) 37– 44
- Mansfield, P.R., see Jureidini, J.N. (1,2) 73– 81
- Marjoribanks, T.K., see Whitstock, M.T. (3) 161–167
- Marks, D.H., P.R. Breggin and D. Braslow, Homicidal ideation causally related to therapeutic medications (4) 231–240
- Matoba, K., see Haga, Y. (4) 241–247
- Matsukura, S., see Haga, Y. (4) 241–247
- McHenry, L.B., see Jureidini, J.N. (1,2) 73– 81
- Ming, L., see Yue, W. (1,2) 51– 56
- Morrato, E.H., B. Curbow, R.M. Crum, C. Nowels and M. Feinleib, Communicating drug risk to physicians: Challenges and opportunities (3) 143–154
- Nagamatsu, Y., see Haga, Y. (4) 241–247
- Nowels, C., see Morrato, E.H. (3) 143–154
- Ofori-Adjei, D., A.N.O. Doodoo, A. Appiah-Danquah and M. Couper, A review of the safety of niclosamide, pyrantel, triclabendazole and oxamniquine (3) 113–122
- Paczynski, R.P., see Kruszewski, S.P. (1,2) 37– 44
- Pearce, C.M., see Whitstock, M.T. (3) 161–167
- Rao, P.G.M., see Jose, J. (3) 169–180
- Savona-Ventura, C., G.G. Buttigieg, S. Grima and M. Vella, Anthropomorphic characteristics as obstetric risk determinants (3) 155–160
- Savona-Ventura, C., see Buttigieg, G.G. (4) 223–230
- Savović, J., see Agbabiaka, T.B. (3) 123–133
- Sawalha, A.F., Self-medication with antibiotics: A study in Palestine (4) 213–222
- Singh, N., E. Dhanaraj, P. Tiwari and A. Bhansali, Attainment of target blood pressure and patterns of antihypertensive therapy in type 2 diabetic hypertensive Asian Indians (1,2) 45– 50
- Sinnott, M., see Fuentes, H. (1,2) 83– 89
- Tiwari, P., see Singh, N. (1,2) 45– 50

- Tonai, T., see Haga, Y. (4) 241–247
- Vella, K., see Buttigieg, G.G. (4) 223–230
- Vella, M., see Savona-Ventura, C. (3) 155–160
- Whitby, M., see Fuentes, H. (1,2) 83– 89
- Whitstock, M.T., E.J. Eckermann, T.K. Marjoribanks and C.M. Pearce, Pharmaceutical economics and politics vs. patient safety: Lumiracoxib in Australia (3) 161–167
- Wu, Z., see Chen, Y. (4) 207–212
- Wu, Z.A., see Chen, Y. (4) 207–212
- Yamanouchi, T., see Haga, Y. (4) 241–247
- Yan, G., see Yue, W. (1,2) 51– 56
- Yoshidomi, K., see Haga, Y. (4) 241–247
- Yue, W., X. Hou-Ming, L. Ming, G. Yan, Y. Bo-Yang and Z. Fan-Dian, Regional pharmacovigilance practice in China (1,2) 51– 56
- Zhang, C., see Chen, Y. (4) 207–212
- Ziganshin, A.U., see Burashnikova, I.S. (1,2) 57– 71
- Ziganshina, L.E., see Burashnikova, I.S. (1,2) 57– 71